{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:57:04Z","timestamp":1790582224750,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      Metastatic castration\u2010resistant prostate cancer has a poor prognosis. Although olaparib has demonstrated efficacy in patients with\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      mutations, real\u2010world data in Japanese patients remain limited. We aimed to evaluate the efficacy and safety of olaparib in patients with BRCA\u2010mutated metastatic castration\u2010resistant prostate cancer and explore the association of\n                      <jats:italic>BRCA2<\/jats:italic>\n                      loss and microsatellite instability status with treatment outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter retrospective study of 34 patients with BRCA\u2010mutated metastatic castration\u2010resistant prostate cancer treated with olaparib between December 2020 and December 2024. The primary endpoint was progression\u2010free survival. Secondary endpoints included overall survival, prostate\u2010specific antigen\u201050 response rate, and safety. Exploratory analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 34 patients, 33 had a\n                      <jats:italic>BRCA2<\/jats:italic>\n                      mutation and one had a\n                      <jats:italic>BRCA1<\/jats:italic>\n                      mutation. Prostate\u2010specific antigen reduction was observed in 76.4% of patients; prostate\u2010specific antigen\u201050 response rate was 58.8%. Median progression\u2010free and overall survival were 15.8 and 35.1\u2009months, respectively. Grade \u2265\u20093 adverse events (most commonly anemia) occurred in 17.6% of patients. Treatment discontinuation due to adverse events occurred in one patient. Exploratory analyses were performed in 23\n                      <jats:italic>BRCA2<\/jats:italic>\n                      \u2010mutated patients who underwent comprehensive genomic profiling.\n                      <jats:italic>BRCA2<\/jats:italic>\n                      loss was observed in 39.1% of patients and showed a trend toward prolonged progression\u2010free survival, whereas microsatellite instability\u2010high status was observed in 13.0% and was associated with shorter progression\u2010free survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Olaparib demonstrated efficacy and safety in Japanese patients with BRCA\u2010mutated metastatic castration\u2010resistant prostate cancer. Exploratory analyses revealed that\n                      <jats:italic>BRCA2<\/jats:italic>\n                      loss may be associated with prolonged progression\u2010free survival, whereas microsatellite instability\u2010high status may be associated with shorter progression\u2010free survival. These findings require validation in larger cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/iju.70626","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:34:57Z","timestamp":1787902497000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010World Outcomes of Olaparib in Japanese Patients With\n                    <scp>BRCA<\/scp>\n                    \u2010Mutated Metastatic Castration\u2010Resistant Prostate Cancer: Exploratory Analysis of\n                    <scp>\n                      <i>BRCA2<\/i>\n                    <\/scp>\n                    Loss and Microsatellite Instability Status"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9902-1694","authenticated-orcid":false,"given":"Takuhisa","family":"Nukaya","sequence":"first","affiliation":[{"name":"Department of Urology Fujita Health University School of Medicine  Toyoake Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7638-6048","authenticated-orcid":false,"given":"Taku","family":"Naiki","sequence":"additional","affiliation":[{"name":"Department of Nephro\u2010Urology Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5186-7139","authenticated-orcid":false,"given":"Hiromitsu","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Urology Hamamatsu University School of Medicine  Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2589-1722","authenticated-orcid":false,"given":"Keita","family":"Nakane","sequence":"additional","affiliation":[{"name":"Department of Urology Gifu University Graduate School of Medicine  Gifu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1351-1315","authenticated-orcid":false,"given":"Teruo","family":"Inamoto","sequence":"additional","affiliation":[{"name":"Department of Urology Hamamatsu University School of Medicine  Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2197-2477","authenticated-orcid":false,"given":"Takahiro","family":"Yasui","sequence":"additional","affiliation":[{"name":"Department of Nephro\u2010Urology Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2980-127X","authenticated-orcid":false,"given":"Takuya","family":"Koie","sequence":"additional","affiliation":[{"name":"Department of Urology Gifu University Graduate School of Medicine  Gifu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4766-2074","authenticated-orcid":false,"given":"Kiyoshi","family":"Takahara","sequence":"additional","affiliation":[{"name":"Department of Urology Fujita Health University School of Medicine  Toyoake Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/bco2.116"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01823-6"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104738"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022485"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyac015"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae003"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.10.022"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.002"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01649"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02704-x"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200043"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-026-00548-8"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1104"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf205"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.05.021"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002007"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-03980-x"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00233"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116733"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15545"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0931"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70626","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/iju.70626","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:29:09Z","timestamp":1790580549000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.70626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/iju.70626"],"URL":"https:\/\/doi.org\/10.1111\/iju.70626","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"2026-06-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70626"}}